INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/003334

A. CLASSIFICATION OF SUBJECT MATTER
Int.Cl⁷ C07K16/28, A61K39/395, A61P7/00, A61P7/04, G01N33/15, G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Facsimile No.

Form PCT/ISA/210 (second sheet) (January 2004)

Minimum documentation searched (classification system followed by classification symbols)
Int.Cl⁷ C07K16/28, A61K39/395, A61P7/00, A61P7/04, G01N33/15, G01N33/50

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
BIOSIS (DIALOG), WPI (DIALOG), JSTPlus (JOIS)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | |
|-----------|---|-----------------------|--|
| Υ . | JP 2001-506135 A (Abbott Laboratories), 15 May, 2001 (15.05.01), | 1-15,18-29 | |
| | & WO 98/28331 A2 | | |
| | & MX 9905856 A1 & US 2001/0006796 A1 | | |
| | & US 6323000 B2 & US 2003/0073161 A1 & US 6683157 B2 | | |
| Y | Ballmaier M. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia., Blood, 2001, Vol.97, No.1, pages 139-46 | 1-15,18-29 | |
| Y | JP 2001-513999 A (Genentech, Inc.), 11 September, 2001 (11.09.01), | 1-15,18-29 | |
| | & WO 99/10494 A2 | | |
| | & EP 1009831 A2 & US 6342220 B1 | | |
| | & AU 755822 B | | |
| - | | | |
| | | | |

| × | Further documents are listed in the continuation of Box C. | | See patent family annex. |
|----------|--|-------|---|
| * "A" | Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance | r.Lo. | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" | earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| - "O" | cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination |
| "P" | document published prior to the international filing date but later than the priority date claimed | "&" | being obvious to a person skilled in the art document member of the same patent family |
| | of the actual completion of the international search 27 May, 2004 (27.05.04) | Date | of mailing of the international search report 15 June, 2004 (15.06.04) |
| | and mailing address of the ISA/ Japanese Patent Office | Auti | norized officer |

Telephone No.

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No

| INTERNATIONAL SEARCH REPORT | | INTERNATIONAL SEARCH REPORT | michanona approacion 140. | | | |
|---|---|---|---|--|--|--|
| | | · | PCT/JP2004/003334 | | | |
| Bo | Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet) | | | | | |
| 1. | . With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of: | | | | | |
| | a . | type of material | | | | |
| | : | × a sequence listing | | | | |
| | | table(s) related to the sequence listing | | | | |
| | b. | format of material | | | | |
| | | in written format | | | | |
| | | in computer readable form | | | | |
| | c. | time of filing/furnishing | | | | |
| contained in the international application as filed | | | | | | |
| | | X filed together with the international application in computer readable form | 1 | | | |
| | | furnished subsequently to this Authority for the purposes of search | | | | |
| 2. | × | In addition, in the case that more than one version or copy of a sequence listing | and/or table relating thereto has been filed | | | |
| | | or furnished, the required statements that the information in the subsequent or a application as filed or does not go beyond the application as filed, as appropriate | dditional copies is identical to that in the e, were furnished. | | | |
| | | | | | | |
| 3. | Add | itional comments: | · | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | • | • | | | | |
| | | | • | | | |
| | | | | | | |
| | | | | | | |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/003334

Concerning the "agonist" as set forth in claim 1, only antibodies, namely a part of the claimed agonists, are supported by the description in the meaning within PCT Article 6 and disclosed therein in the meaning within PCT Article 5.

The same applies to "a substance obtained by a screening method" as set forth in claims 3 to 7, 10, 12 to 15, 23, 24, 26 to 29 and 22. Such being the case, the search was made exclusively on the part

Such being the case, the search was made exclusively on the part supported by the description and disclosed therein, i.e., the antibodies. Claims 2, 8, 9, 11, 18 to 21 and 25 were completely searched.

BEST AVAILABLE COPY